Please login to the form below

Not currently logged in
Email:
Password:

SGLT2 inhibitors

This page shows the latest SGLT2 inhibitors news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

The CHMP decision is based on the results of the CANVAS programme, the largest completed CV outcomes trial to date for any of the SGLT2 inhibitors. ... The first SGLT2 inhibitor to gain this EU label update was Boehringer and Lilly’s Jardiance in

Latest news

More from news
Approximately 3 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    The introduction of a wave of SGLT2 inhibitors will further energise the market - with Novo Nordisk, J&J, Lily, Boehringer, AZ, Merck and Pfizer all due to compete in this space.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    the way SGLT2 inhibitors work by reducing the amount of glucose absorbed in the kidney and passing it out through urine. ... Forxiga is set to face competition from other SGLT2 inhibitors either recently approved or on the horizon, including

  • Pharma deals during April 2013 Pharma deals during April 2013

    The partnership is to co-develop and commercialise Pfizer's phase III ready oral sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin for the treatment of type 2 diabetes, both as a ... SGLT2 inhibitors block the reabsorption of glucose by the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics